Skip to main content

CHA Selects Cepheid as Vendor of Choice for Molecular MRSA Tests

NEW YORK (GenomeWeb News) – Cepheid said yesterday that the Connecticut Hospital Association Shared Services Program for molecular surveillance of methicillin-resistant Staphylococcus aureus has selected Cepheid as its vendor of choice for the tests.
The CHA, which has 164 acute-care member hospitals, will exclusively market Cepheid’s GeneXpert Systems and Xpert MRSA test to its hospitals at pre-negotiated prices.
The program extends beyond Connecticut with member hospitals in eight other states including Massachusetts, Maine, Rhode Island, New Hampshire, Vermont, Illinois, Wyoming, and Iowa. Among these states, Illinois mandates surveillance of MRSA in hospitals, and legislation has been introduced in four of the other states for measures to prevent and control healthcare-associated infections, Cepheid said.
The CHA program includes hospitals with as few as 50 beds and as many as 800 beds, noted Rob Koska, Cepheid’s senior VP of worldwide commercial operations, in a statement.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.